Abstract
Mass spectrometry biomarker discovery may assist patients diagnosis in time and realize the characteristics of new diseases. Our previous work built a preprocess method called HHTmass which is capable of removing noise, but HHTmass only a proof of principle to be peak detectable and did not tested for peak reappearance rate and used on medical data. We developed a modified version of biomarker discovery method called Enhance HHTMass (E-HHTMass) for MALDI-TOF and SELDI-TOF mass spectrometry data which improved old HHTMass method by removing the interpolation and the biomarker discovery process. E-HHTMass integrates the preprocessing and classification functions to identify significant peaks. The results show that most known biomarker can be found and high peak appearance rate achieved comparing to MSCAP and old HHTMass2. E-HHTMass is able to adapt to spectra with a small increasing interval. In addition, new peaks are detected which can be potential biomarker after further validation.
Keywords: Biomarker discovery, Hilbert-Huang transform, MALDI-TOF, Mass spectrometry, SELDI-TOF, HHTmass, MASCAP, Nephrological disease, Urinary hepcidin, Oral cancer:, SpecAlign, Denoising, WEKA, GUI
Protein & Peptide Letters
Title: Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform
Volume: 19 Issue: 1
Author(s): Li-Ching Wu, Ping-Heng Hsieh, Jorng-Tzong Horng, Yu-Jen Jou, Chia-Der Lin, Kuang-Fu Cheng, Cheng-Wen Lin and Shih-Yin Chen
Affiliation:
Keywords: Biomarker discovery, Hilbert-Huang transform, MALDI-TOF, Mass spectrometry, SELDI-TOF, HHTmass, MASCAP, Nephrological disease, Urinary hepcidin, Oral cancer:, SpecAlign, Denoising, WEKA, GUI
Abstract: Mass spectrometry biomarker discovery may assist patients diagnosis in time and realize the characteristics of new diseases. Our previous work built a preprocess method called HHTmass which is capable of removing noise, but HHTmass only a proof of principle to be peak detectable and did not tested for peak reappearance rate and used on medical data. We developed a modified version of biomarker discovery method called Enhance HHTMass (E-HHTMass) for MALDI-TOF and SELDI-TOF mass spectrometry data which improved old HHTMass method by removing the interpolation and the biomarker discovery process. E-HHTMass integrates the preprocessing and classification functions to identify significant peaks. The results show that most known biomarker can be found and high peak appearance rate achieved comparing to MSCAP and old HHTMass2. E-HHTMass is able to adapt to spectra with a small increasing interval. In addition, new peaks are detected which can be potential biomarker after further validation.
Export Options
About this article
Cite this article as:
Wu Li-Ching, Hsieh Ping-Heng, Horng Jorng-Tzong, Jou Yu-Jen, Lin Chia-Der, Cheng Kuang-Fu, Lin Cheng-Wen and Chen Shih-Yin, Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform, Protein & Peptide Letters 2012; 19 (1) . https://dx.doi.org/10.2174/092986612798472929
DOI https://dx.doi.org/10.2174/092986612798472929 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TGF-ß / Smad Signaling in Prostate Cancer
Current Drug Targets Current Developments in the Analysis of Proteomic Data: Artificial Neural Network Data Mining Techniques for the Identification of Proteomic Biomarkers Related to Breast Cancer
Current Proteomics Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Agents Targeting Ras Signaling Pathway
Current Pharmaceutical Design Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Current Medicinal Chemistry Editorial (Thematic Issue: Advances in Drug Discovery for the Treatment of Cancer: Many Approaches, One Goal)
Current Topics in Medicinal Chemistry Targeted Inhibition of AKT in Pancreatic Cancer
Current Cancer Therapy Reviews Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies
Current Pharmacogenomics and Personalized Medicine Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets Glycosidated Phospholipids – a Promising Group of Anti-Tumour Lipids
Anti-Cancer Agents in Medicinal Chemistry Annotation of the Human Genome by High-Throughput Sequence Analysis of Naturally Occurring Proteins
Current Proteomics The Expanding Role of APRIL in Cancer and Immunity
Current Molecular Medicine Synthetic Strategies for the Construction of δ-Carbolines: A Chemical Ladder in Search of Novel Drugs
Current Organic Synthesis Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy
Current Pharmaceutical Design Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design Advances in Hyaluronic Acid-Based Drug Delivery Systems
Current Drug Targets Evolutionary Advantage and Molecular Modes of Action of Multi-Component Mixtures Used in Phytomedicine
Current Drug Metabolism The Role of Copper in Development of Drug Resistance in Murine Carcinoma
Medicinal Chemistry Molecular Imaging in Optical Coherence Tomography
Current Molecular Imaging (Discontinued) Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Current Medicinal Chemistry